Coordinates: 44°40′58″N 63°36′43″W / 44.68278°N 63.61194°W / 44.68278; -63.61194The Bedford Institute of Oceanography (BIO) is a major Government of Canada ocean research facility located in Dartmouth, Nova Scotia. BIO is the largest ocean research station in Canada. Established in 1962 as Canada's first, and currently largest, federal centre for oceanographic research, BIO derives its name from the Bedford Basin, an inland bay comprising the northern part of Halifax Harbour, upon which it is located.Spread out over 40 acres (160,000 m2) of a former Royal Canadian Navy (RCN) property near Shannon Park in Dartmouth, BIO consists of a series of interconnected buildings housing research labs and offices, as well as docks for Canadian Coast Guard and RCN research vessels.As the federal government seeks to concentrate its operations in the Halifax Regional Municipality, BIO is being considered for additional office buildings to house other non-oceanographic and non-research organizations and their employees. As such, new buildings have been built for the Canadian Coast Guard as well as Environment Canada in recent years.
There may be differences in marine migratory patterns between Gaspereau River (GR), Nova Scotia, Canada, Atlantic salmon and salmon originating from other rivers in the inner Bay of Fundy (iBoF) Designatable Unit (DU). Marine migratory patterns are one of several metrics used by managers to determine if the GR Atlantic salmon should remain in the Species At Risk Act protected iBoF DU or if it should be included within the outer Bay of Fundy (oBoF) DU. In this study, 25 female Atlantic salmon kelts of GR genetic strain were obtained from the Coldbrook Biodiversity Facility. The kelts were tagged with acoustic tags and released at the mouth of the GR in May 2019. Of the 25 kelts, 10 were recorded at acoustic receivers on the Scotian Shelf. Five kelts returned to the GR and were recaptured, found to be ripe, and deemed to be consecutive spawners. This included a kelt that logged onto receivers on the Scotian Shelf during June and July, before returning to the GR in October. Depth and migration speed indicated that three kelts may have suffered predation in the oBoF or on the Scotian Shelf, with the tags ingested by a predator. Four kelts moved rapidly out of the Bay of Fundy (BoF) and past the Halifax Line of acoustic receivers in early June 2019. This group migrating early and at characteristic oceanic migratory speeds may represent kelts moving to distant feeding grounds. If so, GR Atlantic salmon may be the only river population in the iBoF inclined to escape high coastal mortality regions for distant oceanic feeding grounds.
This study evaluates the wave energy potential along the Vancouver–Washington–Oregon coastline under different climate change scenarios. Wind and bathymetric data obtained from ECMWF and GEBCO databases were used for the 2000–2015 baseline period, and wave simulations were performed using the MIKE 21 SW model. An unstructured mesh was employed, and model sensitivity to key parameters, including bed roughness, depth-induced wave breaking, and white capping dissipation, was assessed through nine simulation runs. The results indicate that variations in bed roughness and wave breaking exert limited influence on model performance, whereas the inclusion of white capping improves simulation accuracy. Future wave conditions were projected for the 2006–2100 period under the RCP4.5 and RCP8.5 scenarios. The analysis suggests that under the RCP8.5 scenario, increased wind intensity is associated with higher wave power levels compared with present conditions and the RCP4.5 scenario. Furthermore, site-specific analysis at three representative locations along the Vancouver coast indicates that wave energy availability tends to peak during autumn. The findings provide a detailed assessment of wave energy variability under changing climate conditions and offer insights for long-term coastal renewable energy planning.
Developing safe and effective pain medications is an ongoing challenge for human health. Agonists for the µ-opioid receptor (MOR) are essential pain medications, but their high intrinsic efficacy also induces adverse side effects, including respiratory depression, constipation, tolerance, dependence, withdrawal and addiction1-7. Strategies to limit adverse effects traditionally include developing MOR agonists that have low intrinsic efficacy or that preferentially activate G-protein signalling over β-arrestin signalling8. Here we identify a novel MOR agonist with supramaximal intrinsic efficacy and a unique pharmacological profile that produced effective analgesia in rodents with minimal adverse effects. N-desethyl-fluornitrazene (DFNZ) was derived from a class of synthetic benzimidazole opioids called nitazenes. DFNZ has impaired brain penetrance, a unique spatiotemporal MOR cellular signalling profile, and diminished efficacy at the MOR-galanin 1 receptor (GAL1) heteromer. DFNZ does not induce respiratory depression, tolerance or MOR downregulation after repeated exposure. Compared with other MOR agonists, DFNZ has limited effects on dopamine neurotransmission in nucleus accumbens and weaker reinforcing effects in the drug self-administration procedure. These results provide novel insights about MOR and nitazene pharmacology, have important implications for pain and addiction treatment, and challenge the prevailing dogma that high-efficacy MOR agonists cannot constitute safe and effective therapeutic agents.
Background and aims Lipoprotein(a) (Lp(a)) is a proatherogenic particle that is considered an important cardiovascular risk modifier due to its association with atherosclerotic cardiovascular disease (ASCVD) as well as calcific aortic valve stenosis (CAVS). Data on the clinical burden associated with elevated lipoprotein(a) levels in patients at high and very high cardiovascular risk remain limited. We evaluated the prevalence of ASCVD and LDL-C target achievement in subjects with high and very high elevated Lp(a) levels referred to a lipid unit. Methods and results In this retrospective study, 1755 subjects were evaluated; 265 with Lp(a) ≥240nmol/L were included. The population was divided into two groups: high Lp(a) (240–429nmol/L, n=216) and very high Lp(a) (≥430nmol/L, n=49). ASCVD prevalence was 58% in the very high group and 48% in the high group (p=0.23). Age and statin intensity were higher in the very high Lp(a) group. LDL-C target achievement was low in both groups: 20.0% and 25.4% of very high-risk patients reached <55mg/dL as well as 18.2% and 17.2% of high-risk patients reached <70mg/dL in very high and high Lp(a) groups, respectively. Conclusions Subjects with elevated Lp(a) levels showed a high prevalence of ASCVD and low LDL-C target attainment despite high-intensity statin therapy. These findings support the need for Lp(a) screening and additional lipid-lowering strategies in high-risk patients.
BACKGROUND:Klebsiella pneumoniae is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, contributing substantially to the overall burden of antimicrobial-resistant infections and mortality among neonates globally. Pathogen sequencing has been used to investigate case clusters and confirm nosocomial transmission in a small number of neonatal units. Here we utilise pathogen sequence data to estimate the fraction of K. pneumoniae neonatal sepsis attributable to nosocomial transmission in African and South Asian countries. METHODS AND FINDINGS:We estimated the proportion of invasive K. pneumoniae disease involved in nosocomial transmission clusters in a given neonatal unit, using single-linkage clustering based on pairwise temporal and genetic distances estimated from bacterial whole-genome sequences aggregated from 10 contributing studies. Analysing 1,523 K. pneumoniae isolates from 27 units in 13 countries in Africa and South Asia between 2013 and 2023, we inferred 156 nosocomial transmission clusters, ranging from 2 to 188 neonates each (83 of the clusters comprised ≥3 cases). Overall, we estimated that 1,035 neonatal infections (68.0%) were part of nosocomial transmission clusters. Excluding the first infection in each cluster as a potential index case, we estimate at least 879 (57.7%) infections were acquired via nosocomial transmission. Sensitivity analyses showed that results were robust to the choice of genetic distance estimation methods and thresholds used to define clusters, and cluster estimates were stable over temporal distance thresholds ranging from 2 to 8 weeks. Isolates were mostly extended-spectrum beta-lactamase (ESBL) producers (90.9%) and included 172 multi-locus sequence types (STs). Fourteen STs, including several globally recognised multidrug-resistant lineages, were associated with transmission clusters at multiple units, and these were collectively responsible for two-thirds of all infections. Carriage of carbapenemase genes (adjusted odds ratio, aOR = 2.08 [95% confidence interval, CI: 1.04, 4.14]; p = 0.04) and ESBL genes (aOR = 2.48 [95% CI: 1.26, 4.90]; p = 0.006) were significantly positively associated with transmission in a logistic regression model with site as a covariate. Limitations of this study include the lack of sufficient clinical data to allow high-resolution investigation of transmission dynamics and lack of facility-level data to investigate contributors to the observed differences in transmission burden across sites. CONCLUSIONS:Nosocomial transmission contributes to a substantial proportion of K. pneumoniae sepsis in neonatal care units in Africa and South Asia. Reducing transmission within these settings through improved infection prevention and control and other measures could substantially reduce the neonatal sepsis burden. A high burden of transmission clusters is associated with the same drug-resistant lineages that are recognised as high-risk clones associated with hospital outbreaks in high-income countries, indicating global connectivity of the antimicrobial-resistant pathogen population.
